ZMYM3突变通过组蛋白乙酰化与NOTCH1协同促进慢性淋巴细胞白血病
该研究对487例CLL患者进行二代测序,发现32个ZMYM3变异且以功能丧失为主,ZMYM3突变与NOTCH1突变富集相关(60%携带NOTCH1突变)。临床上ZMYM3突变需治疗比例更高、至首次治疗时间更短,是多变量分析中的独立不良预后因素;机制上其与NOTCH1协同引起转录失调和组蛋白乙酰化降低,原代细胞对BCL-XL抑制剂和依鲁替尼更敏感。
要点
- ZMYM3突变多为功能丧失变异,60%伴NOTCH1突变。
- ZMYM3突变提示更高治疗需求和更短至首次治疗时间。
- 原代ZMYM3突变CLL细胞对BCL-XL抑制和依鲁替尼更敏感。
核心结论
- ZMYM3突变是CLL的独立不良预后因素,并与NOTCH1突变协同影响转录和组蛋白乙酰化。
研究设计与样本
- 对487例CLL患者进行二代测序分析ZMYM3变异,并采用CRISPR/Cas9编辑的CLL细胞及RNA测序进行功能研究。
主要发现
- 487例中鉴定出32个ZMYM3变异,以功能丧失变异为主,60%的ZMYM3突变患者携带NOTCH1突变。
- ZMYM3突变患者至首次治疗时间中位35个月 vs 53个月(P = .010),早期患者中位48个月 vs 108个月(P = .002)。
- 多变量分析证实ZMYM3突变为独立不良预后因素。
- ZMYM3突变与NOTCH1突变协同引起广泛转录失调,并影响组蛋白乙酰化、降低染色质可及性。
- ZMYM3突变通过下调caspase促进凋亡逃逸,原代ZMYM3突变CLL细胞对BCL-XL抑制和依鲁替尼敏感性增加。
临床怎么用
- ZMYM3突变可辅助CLL危险分层,尤其用于早期患者预后判断。
- ZMYM3突变CLL细胞对BCL-XL抑制和依鲁替尼敏感性增加,可能提示治疗选择方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ZMYM3 mutations have been recurrently identified in patients with chronic lymphocytic leukemia (CLL) at diagnosis. However, their clinical relevance and functional implications remain poorly defined. In this study, we comprehensively characterize the clinical and translational impact of ZMYM3 mutations in CLL. Next-generation sequencing analyses of 487 CLL patients identified 32 ZMYM3 variants, which predominantly manifested as loss-of-function variants. Patients with ZMYM3-mutated CLL showed a strong enrichment of NOTCH signaling pathway alterations, with 60% harboring NOTCH1 mutations. Clinically, ZMYM3 variants were associated with a higher treatment requirement and a significantly shorter time to first treatment (median, 35 vs 53 months; P = .010) and stratified clinical outcome among early-stage patients (median, 48 vs 108 months; P = .002). Multivariable analysis confirmed ZMYM3 mutations as an independent adverse prognostic factor. Using CRISPR/Cas9-edited CLL cells, we demonstrated that ZMYM3 mutations cooperate with NOTCH1 mutations to induce widespread transcriptional dysregulation. Moreover, RNA-sequencing of cellular models and samples from patients with CLL further revealed that ZMYM3 mutations impact histone acetylation, resulting in reduced chromatin accessibility. Functionally, ZMYM3 mutations promoted apoptosis evasion through caspase downregulation. Importantly, primary ZMYM3-mutated CLL cells exhibited increased sensitivity to BCL-XL inhibition and ibrutinib. Overall, this work establishes the clinical relevance of ZMYM3 mutations and provide novel insights into their contribution to CLL pathophysiology.
引用
- Rodríguez-Sánchez A, Pérez-Carretero C, Corchete-Sánchez LA, et al. ZMYM3 mutations modulate histone acetylation and cooperate with NOTCH1 mutations in chronic lymphocytic leukemia. Blood Adv. 2026. PMID: 42269081. doi:10.1182/bloodadvances.2025019501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。